2017 Pipeline Review for Bladder and Ureter Cancer Drug Development

DUBLIN, March 29, 2018 /PRNewswire/ --

The "Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" report has been added to ResearchAndMarkets.com's offering.

The report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.

Bladder Cancer: There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.

Ureter or Ureteral Cancer: There are a total of nine products in development for this indication, by six companies and two academic institutions.

Scope

• Which companies are the most active within each pipeline?
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to Buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Key Topics Covered

1 Table of Contents

2 Introduction
2.1 Bladder and Ureter Cancer Report Coverage
2.2 Ureter Cancer - Overview
2.3 Bladder Cancer - Overview

3 Therapeutics Development
3.1 Ureter Cancer
3.2 Bladder Cancer

4 Therapeutics Assessment
4.1 Ureter Cancer
4.2 Bladder Cancer

5 Companies Involved in Therapeutics Development
5.1 Ureter Cancer
5.2 Bladder Cancer

6 Dormant Projects
6.1 Bladder Cancer

7 Discontinued Products
7.1 Bladder Cancer

8 Product Development Milestones
8.1 Ureter Cancer
8.2 Bladder Cancer

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

Companies Mentioned

• 4SC AG
• ADC Therapeutics Sarl
• ANP Technologies Inc
• APIM Therapeutics AS
• AVEO Pharmaceuticals Inc
• Abivax SA
• Adaptimmune Therapeutics Plc
• Altor BioScience Corp
• AndroScience Corp
• Archivel Farma SL
• Argos Therapeutics Inc
• Arno Therapeutics Inc
• Array BioPharma Inc
• Asana BioSciences LLC
• Asieris Pharmaceuticals Co Ltd
• Astellas Pharma Inc
• Astex Pharmaceuticals Inc
• AstraZeneca Plc
• Bavarian Nordic A/S
• Bayer AG
• BioCancell Ltd
• Biocad
• Biohaven Pharmaceutical Holding Company Ltd
• Biomics Biotechnologies Co Ltd
• Biotest AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Co
• Celgene Corp
• Celldex Therapeutics Inc
• Celprogen Inc
• Celsion Corp
• Celyad SA
• Cleveland BioLabs Inc
• Cold Genesys Inc
• Corvus Pharmaceuticals Inc
• CytomX Therapeutics Inc
• Cytori Therapeutics Inc
• Daiichi Sankyo Co Ltd
• Eisai Co Ltd
• Eleven Biotherapeutics Inc
• Eli Lilly and Co
• Elsalys Biotech SAS
• EpiThany Inc
• Esperance Pharmaceuticals Inc
• Exelixis Inc
• Exicure Inc
• F. Hoffmann-La Roche Ltd
• Five Prime Therapeutics Inc
• Gene Signal International SA
• Genentech Inc
• Genmab A/S
• GlaxoSmithKline Plc
• H3 Biomedicine Inc
• Hamlet Pharma AB
• Hanmi Pharmaceuticals Co Ltd
• HitGen LTD
• Horizon Pharma Plc
• Immunocore Ltd
• Immunomedics Inc
• Immupharma Plc
• Imugene Ltd
• Incanthera Ltd
• Incyte Corp
• Innovation Pharmaceuticals Inc
• InteRNA Technologies BV
• Iovance Biotherapeutics Inc
• Johnson & Johnson
• Kite Pharma Inc
• Laboratoires Pierre Fabre SA
• LipoMedix Pharmaceutical Inc
• Loxo Oncology Inc
• Lycera Corp
• MTG Biotherapeutics Inc
• MacroGenics Inc
• Marina Biotech Inc
• MaxiVAX SA
• MedImmune LLC
• Medicenna Therapeutics Corp
• Merck & Co Inc
• Mirati Therapeutics Inc
• Moleculin Biotech Inc
• NanoCarrier Co Ltd
• NantKwest Inc
• Nektar Therapeutics
• Novartis AG
• OncoTherapy Science Inc
• Oncovir Inc
• Ono Pharmaceutical Co Ltd
• Optimum Therapeutics LLC
• Oxford BioTherapeutics Ltd
• Pfizer Inc
• Pharma Mar SA
• Philogen SpA
• Pieris Pharmaceuticals Inc
• Plexxikon Inc
• Polaris Pharmaceuticals Inc
• Provecs Medical GmbH (Inactive)
• Provectus Biopharmaceuticals Inc
• PsiOxus Therapeutics Ltd
• Rexahn Pharmaceuticals Inc
• Samyang Holdings Corp
• Sanofi
• Sareum Holdings Plc
• Shionogi & Co Ltd
• Sierra Oncology Inc
• Sillajen Biotherapeutics
• Sitka Biopharma Inc
• Sorrento Therapeutics Inc
• Spectrum Pharmaceuticals Inc
• Stemline Therapeutics Inc
• Sun Pharma Advanced Research Company Ltd
• Taiwan Liposome Company Ltd
• Taris Biomedical LLC
• Theralase Technologies Inc
• Tocagen Inc
• Tolero Pharmaceuticals Inc
• Transgene SA
• UroGen Pharma Ltd
• Vaccibody AS
• Vakzine Projekt Management GmbH
• Vault Pharma Inc
• Vaxeal Holding SA
• Vaxiion Therapeutics Inc
• Viralytics Ltd
• Vyriad Inc
• Zymeworks Inc

For more information about this report visit https://www.researchandmarkets.com/research/gzqzsn/2017_pipeline?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2017-pipeline-review-for-bladder-and-ureter-cancer-drug-development-300621610.html

SOURCE Research and Markets